Abstract:Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed. In this study, we investigated whether epigenetic reprograming by modulating histone methylation could enhance effector T lymphocyte trafficking and improve therapeutic efficacy of immune checkpoint blockade in breast cancer with focus on triple-negative breast cancer (TNBC) subtype. In silico analysis of The Cancer Genome Atlas (TCGA) data shows that expression of histone lysine-specific demethylase 1 (LSD1) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemokine ligand 5 (CCL5), C-X-C motif chemokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens. Tiling chromatin immunoprecipitation study showed that re-expression of chemokines by LSD1 inhibition is associated with increased H3K4me2 levels at proximal promoter regions. Rescue experiments using concurrent treatment with small interfering RNA or inhibitor of chemokine receptors blocked LSD1 inhibitor-enhanced CD8+ T cell migration, indicating a critical role of key T cell chemokines in LSD1-mediated CD8+ lymphocyte trafficking to the tumor microenvironment. In mice bearing TNBC xenograft tumors, anti-PD-1 antibody alone failed to elicit obvious therapeutic effect. However, combining LSD1 inhibitors with PD-1 antibody significantly suppressed tumor growth and pulmonary metastasis, which was associated with reduced Ki-67 level and augmented CD8+ T cell infiltration in xenograft tumors. Overall, these results suggest that LSD1 inhibition may be an effective adjuvant treatment with immunotherapy as a novel management strategy for poorly immunogenic breast tumors.

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential

LSD1: an Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy

Priming with LSD1 Inhibitors Promotes the Persistence and Antitumor Effect of Adoptively Transferred T Cells

Targeting LSD1 in cancer: Molecular elucidation and recent advances

Therapeutic potential of targeting LSD1/ KDM1A in cancers

Pharmacological Inhibition of LSD1 for Cancer Treatment

Lysine-specific Histone Demethylase 1 (LSD1): A Potential Molecular Target for Tumor Therapy

Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti–PD-1 Treatment

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

LSD1 inhibitors for anticancer therapy: a patent review (2017-present)

LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness

Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC

Targeting LSD1 for acute myeloid leukemia (AML) treatment

LSD1 Silencing Contributes to Enhanced Efficacy of Anti-Cd47/pd-l1 Immunotherapy in Cervical Cancer.

LSD1 is a promising target to treat cancers by modulating cell stemness

Recent advances in inhibitors of lysine specific demethylase 1 in tumor therapies

Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade

Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives

E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials